Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
LN

Laura Nisenbaum

Interim Chief Science Officer, Alzheimer's Drug Discovery Foundation

Appears in 1 story

Notable Quotes

This is the first signal that we might be able to move beyond amyloid.

Stories

Biogen's tau drug slows Alzheimer's decline in first-of-its-kind trial

New Capabilities

Independent voice assessing the field

For decades, nearly every Alzheimer's drug that reached patients aimed at one target: a sticky protein called amyloid. On July 14, 2026, Biogen showed the first clinical evidence that hitting a different protein, tau, can also slow the disease.

Updated 1 hour ago